Innovation & Research

Menarini, focused on making a difference

For over 30 years, Menarini has been driving research and development to deliver innovative and effective medicines and healthcare solutions for patients affected by serious health conditions. At Menarini we understand that patients’ hope for a better life is inextricably linked to the persistence and progress of our researchers – that is what drives us forward.

With 9 research centers across Europe, the US and Southeast Asia, MENARINI R&D develops projects from the preclinical phase to drug registration.

Our Approach to R&D

Our R&D division is focused on developing innovation in life sciences to improve the health of patients. In collaboration with our Business Development & Licensing and Marketing teams, we identify the most promising opportunities and apply our expertise in drug development to transform them into high-quality medicines that will improve patients’ lives.


Continued investments in technology and in enhancing the skills and knowledge of our researchers means that we can deliver scientific breakthroughs and meaningfully contribute to finding cures for difficult-to-treat diseases.

Innovation & Research

Our research areas

We are strengthening our pipeline with a focus on science related to oncology and infectious diseases, two areas where we are well positioned to develop innovative therapies and to bring to patients in need.

Oncology

Working tirelessly to give hope to patients with difficult to treat cancers

READ MORE

Infectious Diseases

Committed to contributing to the fight against antimicrobial resistance

READ MORE

precision medicine

Our pipeline and products

Menarini is investing in advanced science and technology to develop a pipeline of new products that make a difference to the lives of patients affected by serious conditions.

Read More



Clinical trials

The Menarini Group is committed to enhancing public health trough responsible sharing of clinical trial data.

Read More
Clinical trials


Partnering

Drug development is a challenging process, and success relies on the integration of innovative scientific discoveries with the necessary capabilities and resources to transform them into effective healthcare solutions.

Read More

"Use the key combination "ctrl" + "mouse wheel" or the "+" and "-" buttons at the bottom right to browse the map"

2023 - 9 - 20

European Commission Approves Menarini Group’s ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation

FLORENCE (Italy) and NEW YORK, NY, September 20, 2023 – The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline...
Read more

2023 - 8 - 30

The Menarini Group Announces ELZONRIS® (Tagraxofusp) Designated as an Orphan Drug for BPDCN by Japanese Ministry of Health, Labor and Welfare

FLORENCE (Italy) and New York, NY, August 30, 2023 – The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline...
Read more

2023 - 7 - 21

Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer

FLORENCE (Italy) and NEW YORK, NY, July 21, 2023 – The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline...
Read more